Excess cardiovascular risk varies with age at diagnosis of type 1 diabetes.
Patients with remitted bipolar disorder and emotional hyper-reactivity also have significantly higher levels of low-grade inflammation, hypertension, and impaired glucose metabolism, indicating a higher risk for cardiometabolic dysfunction.
Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.
Increased mortality risks were limited to the first post-HT year because increases in risks markedly decreased when the follow-up time was extended over more than 1 year.
Losing weight may result in a decrease of heart muscle thickness.
The most effective approaches to CVD self-management were tailored to individual patient needs and incorporated a multidisciplinary approach.
The FDA is poised to review data from the DEVOTE trial, examining the rates of major adverse cardiovascular events in insulin degludec vs insulin glargine.
A common variant in the sulfonylurea receptor has been associated with a reduced risk of both type 2 diabetes and coronary heart disease.
There has been growing concern that testosterone replacement therapy is associated with adverse cardiovascular outcomes.
As achieved glycated hemoglobin A1c levels increased, the risk for a combined cardiovascular event increased.
Recent evidence clearly indicates that patients should be eating whole foods rather than attempting to get vitamins and antioxidants from dietary supplements.
Higher levels of free T4 were associated with atrial fibrillation, but TSH and total T3 were not.
Transgender men who are on long-term androgen therapy have higher levels of aortic stiffness, which may increase their risk for cardiovascular events.
Older patients with diabetes whose hemoglobin A1c levels were greater than 8% had an increased mortality risk.
A cohort study of primary care records in the United Kingdom did not find an increased risk of major cardiovascular events in patients with type 2 diabetes treated with insulin.
A stratification tool identifies risk factors in patients who may benefit from the addition of ezetimibe to their statin therapy.
Blood pressure trajectory monitoring can provide "an important approach" to identify those at high risk of developing hypertension and CVD, according to study investigators.
The American Heart Association releases a new statement suggesting that eating more earlier in the day may be healthier
Researchers set out to determine whether or not aspirin therapy in type 2 diabetes is effective.
Chronic stress identified as risk factor for cardiovascular disease.
Sitagliptin has a neutral effect on cardiovascular risk among older patients with type 2 diabetes.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Mid upper arm circumference is an independent predictor of survival in older adults with cardiovascular disease.
Postprandial hyperglycemia is linked to cardiovascular disease in patients with type 2 diabetes, regardless of HbA1c.
The US Preventive Services Task Force (USPSTF) recommends that certain adults aged 40 to 75 years without cardiovascular disease (CVD) history but with 1 or more cardiovascular (CV) risk factors initiate statins.
There is a graded association between intensity of statin therapy and mortality for patients with established atherosclerotic cardiovascular disease.
Calcium supplements, taken within recommended levels, can be considered safe for the heart, according to new guidelines and an evidence review published in the Annals of Internal Medicine.
Statins can interact with other drugs prescribed for cardiovascular disease, but there are ways to navigate the issue.
Study finds no significant difference in 10-year cardiovascular risk.
Young adults with long-standing, childhood-onset type 1 diabetes have increased total and cardiovascular disease mortality.
Endocrinology Advisor Articles
- Trends in Cardiovascular Deaths for US Adults With and Without Diabetes
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Comparing Efficacies of Second-Line Treatments in Type 2 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency